A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.

Rianne J Hendriks, Marloes M G van der Leest, Siebren Dijkstra, Jelle O Barentsz, Wim Van Criekinge, Christina A Hulsbergen-van de Kaa, Jack A Schalken, Peter F A Mulders, Inge M van Oort,


The Prostate, August 30, 2017


Prostate cancer (PCa) diagnostics would greatly benefit from more accurate, non-invasive techniques for the detection of clinically significant disease, leading to a reduction of over-diagnosis and over-treatment. The aim of this study was to determine the association between a novel urinary biomarker-based risk score (SelectMDx), multiparametric MRI (mpMRI) outcomes, and biopsy results for PCa detection. This retrospective observational study used data from the validation study of the SelectMDx score, in which urine was collected after digital rectal examination from men undergoing prostate biopsies. A subset of these patients also underwent a mpMRI scan of the prostate. The indications for performing mpMRI were based on persistent clinical suspicion of PCa or local staging after PCa was found upon biopsy. All mpMRI images were centrally reviewed in 2016 by an experienced radiologist blinded for the urine test results and biopsy outcome. The PI-RADS version 2 was used. In total, 172 patients were included for analysis. Hundred (58%) patients had PCa detected upon prostate biopsy, of which 52 (52%) had high-grade disease correlated with a significantly higher SelectMDx score (P 

© 2017 Wiley Periodicals, Inc.


Pubmed Link: 28853167

DOI: 10.1002/pros.23401